Recommended Liver Test Frequency for Tigecycline
Tigecycline (Tygacil), an intravenous glycylcycline antibiotic, requires monitoring of liver function tests (LFTs) due to risks of elevated transaminases and rare hepatotoxicity. The prescribing information recommends checking liver tests prior to therapy initiation and routinely during treatment.[1]
- Baseline: Obtain LFTs (ALT, AST, bilirubin, alkaline phosphatase) before starting tigecycline.
- During therapy: Perform LFTs periodically, typically every 1-2 weeks or more frequently if baseline abnormalities exist, patient risk factors (e.g., liver disease, concurrent hepatotoxins) are present, or clinical signs of liver issues emerge. No fixed interval is mandated; clinicians adjust based on patient-specific factors like duration of therapy (often 5-14 days for approved infections).[1][2]
Discontinue tigecycline if transaminases exceed 3x upper limit of normal (ULN) without other causes, or 5x ULN with symptoms.[1]
Why Monitor Liver Tests with Tigecycline?
Tigecycline can cause asymptomatic elevations in ALT/AST (up to 2-3x ULN in 5-10% of patients in trials), more common in longer courses or complicated intra-abdominal infections. Hepatic adverse events occurred in 3-7% of trial patients, prompting label warnings.[1][3]
Risk Factors Triggering More Frequent Testing
Increase testing frequency (e.g., weekly or twice-weekly) for:
- Pre-existing liver impairment.
- Prolonged therapy beyond 14 days (off-label use).
- Concomitant drugs like statins or other antibiotics.
- Elderly patients or those with sepsis, where rates of LFT abnormalities rise to 15%.[2][3]
What Do Clinical Guidelines Say?
IDSA guidelines for infections like complicated skin/soft tissue or intra-abdominal (where tigecycline is used) emphasize LFT monitoring but defer to product labeling without specifying intervals. Local hospital protocols often standardize to weekly checks during IV therapy.[2]
Comparison to Other Tetracyclines
Unlike doxycycline (minimal liver monitoring needed), tigecycline's IV formulation and biliary excretion heighten hepatotoxicity risk, necessitating stricter surveillance than oral tetracyclines.[3]
[1]: Tygacil Prescribing Information (Pfizer)
[2]: IDSA Guidelines on Skin and Soft Tissue Infections
[3]: DrugPatentWatch.com - Tigecycline Profile